Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer
- 1 March 2010
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 5 (3) , 320-325
- https://doi.org/10.1097/jto.0b013e3181ce684f
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancerLung Cancer, 2008
- Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- DNA Repair and Survival in Lung Cancer — The Two Faces of JanusNew England Journal of Medicine, 2007
- DNA Synthesis and Repair GenesRRM1andERCC1in Lung CancerNew England Journal of Medicine, 2007
- ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabineAnnals of Oncology, 2006
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Vinorelbine Plus Cisplatin Versus Docetaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized TrialJournal of Clinical Oncology, 2005
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.Journal of Clinical Investigation, 1997
- Structure and Utilization of Tubulin IsotypesAnnual Review of Cell Biology, 1988